Articles tagged "Islets"

2017 American Transplant Congress
Bioengineering Human Islets to Form Peri-Islet Vessels from Intraislet Endothelial Cells for Improving Human Islet Function.
G. Loganathan, S. Narayanan, M. Dhanasekaran, A. Patel, W. Tucker, M. Hughes, S. Williams, A. Balamurugan.
Clinical Islet Laboratory, Dept. of Surgery, Cardiovascular Innovation Institute, University of Louisville, KY
Native islets in the pancreas have a rich vascular supply however, the current islet isolation technique completely severs the vasculature to islets. As such, these…
2017 American Transplant Congress
Recognition of Islet Xenografts In Vivo by Non-Obese Diabetic (NOD) Insulin-Specific CD4 T Cells.
R. Gill, W. Dale, M. Crawford.
Surgery and Immunology, University of Colorado Denver, Aurora, CO
Xenogeneic islet transplantation has been one ongoing goal for treating autoimmune Type 1 diabetes. Autoimmune diabetes involves a T cell response restricted to the host…
2017 American Transplant Congress
IP-10 Monoclonal Antibody Treatment Suppresses Inflammatory Components of IBMIR and Improves Pancreatic Islet Graft Function.
G. Yoshimatsu,¹ C. Chang,¹ C. Darden,¹ P. Saravanan,¹ B. Naziruddin,² M. Lawrence.¹
¹Baylor Scott and White Reseasrch Institute, Dallas, TX; ²Baylor Simmons Transplant Institute, Dallas, TX
Introduction: An instant blood-mediated inflammatory response (IBMIR) causes acute loss of pancreatic islets. Interferon gamma-induced protein 10 (IP-10) is a key proinflammatory chemokine that may…
2017 American Transplant Congress
Islet Rejection in Autoimmune NOD Mouse Recipients: Implications for Stem Cell Therapies.
R. Gill,¹ M. Coulombe,¹ T. Kupfer,¹ K. Beard,¹ A. Burrack.²
¹Surgery and Immunology, University of Colorado Denver, Aurora, CO; ²University of Minnesota, Minneapolis, MN
Several efforts are ongoing to use stem cell precursors to generate islet-like tissues suitable for transplantation in autoimmune Type 1 diabetic (T1D) recipients. During the…
2017 American Transplant Congress
Thrombalexin and Mirococept Synergistically Reduce IBMIR in a Porcine to Rhesus Xenoislet Model.
M. Manook,^1,2 J. Kwun,¹ J. Yoon,¹ K. Samy,¹ A. MacDonald,¹ H. Xu,¹ R. Smith,³ A. Dorling,³ A. Kirk,¹ N. Mamode,² S. Knechtle.¹
¹Surgery, Duke Transplant Center, Durham, NC; ²Renal and Transplant, Guy's and St Thomas'NHS Foundation Trust, London, United Kingdom; ³MRC Centre for Transplantation, King's College, London, United Kingdom
Introduction: Early activation of coagulation and complement are important factors in the initiation of instant blood mediated inflammation (IBMIR) in xenoislet models. Two novel 'cytotopic'…
2017 American Transplant Congress
Immunosuppressive Role of Pancreas Derived Mesenchymal Stem Cells.
M. Kanak,¹ F. Kunnathodi,² M. Levy,^1,3 M. Lawrence,² B. Naziruddin.⁴
¹Transplant Surgery, Virginia Commonwealth University, Richmond, VA; ²Baylor Research Institute, Dallas, TX; ³Hume-Lee Transplant Center, VCU Health System, Richmond, VA; ⁴Simmons Transplant Institute, Baylor Scott and White Health, Dallas, TX
BackgroundThe Edmonton protocol revived islet transplantation therapy for Type-1 Diabetic patients. However, Long-term islet function still remains a challenge. Immunosuppression used after islet transplantation contributes…
2017 American Transplant Congress
Long-Term Drug-Free Survival of Tiny Cynomolgus Islet Allografts.
M. Koulmanda, V. Chipashivili, M. Duggan, T. Strom.
Surgery and Medicine, Beth Israel Deaconess Medical Center, Boston, MA; Surgery, Massachusetts General Hospital, Boston, MA
Following upon highly beneficial effects observed with short-term alpha 1-antitrypsin (AAT) treatment in the marginally sized autologous cynomolgus islet transplant model, we are testing the…
2017 American Transplant Congress
CD4⁺/CD8⁺ T Cell Ratio as a Predictive Marker for Early Graft Failure in Pig to Non-Human Primate Islet Xenotransplantation with Immunosuppression.
S. Choi,^1,3,4 H.-J. Kim,^1,2,3,4 I.-H. Yoon,^1,2 J.-S. Kim,^1,2,6 S.-J. Kang,^1,2,3,4 H.-Y. Nam,^1,2 B.-H. Min,¹ J.-S. Shin,^1,6 J.-M. Kim,^1,6 Y.-H. Kim,^1,5 W.-W. Lee,^1,2,3,4 C.-G. Park.^1,2,3,4,6
¹Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea; ²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; ³Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea; ⁴Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea; ⁵Department of Microbiology, Kyungpook National University School of Medicine, Daegu, Korea; ⁶Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul, Korea
Background: Outstanding results from nonhuman primate study put islet xenotransplantation with immunosuppression closer to the clinical application. To establish successful immune suppressive protocols, immune monitoring…
2017 American Transplant Congress
Next-Generation Sequencing-Based Exosome MicroRNA Profiling for Specific Identification of Islet Damage.
P. Saravanan,¹ J. Gu,¹ X. Wang,¹ P. Nguyen,¹ G. Yoshimatsu,¹ M. Lawrence,¹ B. Naziruddin.²
¹Baylor Scott and White Research Institute, Dallas, TX; ²Baylor Simmons Transplant Institute, Dallas, TX
Introduction: A significant mass of intraportally transplanted islets undergo damage due to various stress conditions including hypoxia and inflammation. Development of innovative ultrasensitive tests to…
2017 American Transplant Congress
Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes (T1D) Post Renal Transplantation.
J. Markmann, R. Alejandro, M. Bellin, N. Bridges, W. Clarke, T. Eggerman, E. Foster, B. Hering, D. Kaufman, O. Korsgren, X. Luo, A. Naji, J. Oberholzer, A. Posselt, M. Rickels, C. Ricordi, M. Robien, P. Senior, A. Shapiro, N. Turgeon.
CIT Consortium
Introduction: From a risk-benefit perspective, patients with type 1 diabetes (T1D) who are already obligated to long-term immunosuppression to support a kidney transplant and who…